Yixintang Pharmaceutical Group Co., Ltd.
Символ: 002727.SZ
SHZ
18.75
CNYПазарна цена днес
21.9415
Съотношение P/E
0.6400
Коефициент PEG
11.17B
MRK Cap
- 0.02%
Доходност на DIV
Yixintang Pharmaceutical Group Co., Ltd. (002727-SZ) финансови отчети
Баланс
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 13372.53 | 3334.5 | 3520 | 2532.4 | |||||||||||||||
balance-sheet.row.short-term-investments | 6694.1 | 6669 | 8.4 | 297.3 | |||||||||||||||
balance-sheet.row.net-receivables | 6672.97 | 0 | 2411 | 1777.5 | |||||||||||||||
balance-sheet.row.inventory | 11464.07 | 0 | 3387.4 | 3317 | |||||||||||||||
balance-sheet.row.other-current-assets | 342.65 | 0 | 139.2 | 65.5 | |||||||||||||||
balance-sheet.row.total-current-assets | 31852.22 | 3334.5 | 9457.6 | 7692.4 | |||||||||||||||
balance-sheet.row.property-plant-equipment-net | 11656.93 | 0 | 3993.5 | 4080 | |||||||||||||||
balance-sheet.row.goodwill | 4384.23 | 0 | 1397.2 | 1380 | |||||||||||||||
balance-sheet.row.intangible-assets | 500.49 | 0 | 165.7 | 122.9 | |||||||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 4884.72 | 0 | 1562.9 | 1502.8 | |||||||||||||||
balance-sheet.row.long-term-investments | 371.67 | 0 | 131.4 | -190.1 | |||||||||||||||
balance-sheet.row.tax-assets | 292.8 | 0 | 94.1 | 58.5 | |||||||||||||||
balance-sheet.row.other-non-current-assets | -453.91 | -3334.5 | 939.5 | 1193.8 | |||||||||||||||
balance-sheet.row.total-non-current-assets | 16752.2 | -3334.5 | 6721.5 | 6645 | |||||||||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | |||||||||||||||
balance-sheet.row.total-assets | 48604.43 | 0 | 16179.1 | 14337.3 | |||||||||||||||
balance-sheet.row.account-payables | 12654.33 | 0 | 4328.8 | 3805.9 | |||||||||||||||
balance-sheet.row.short-term-debt | 3740.63 | 0 | 1335.5 | 1143.9 | |||||||||||||||
balance-sheet.row.tax-payables | 486.11 | 0 | 250.4 | 164.1 | |||||||||||||||
balance-sheet.row.long-term-debt-total | 5599.1 | 0 | 1758.5 | 1764.1 | |||||||||||||||
Deferred Revenue Non Current | 33.4 | 0 | 12.2 | 13.3 | |||||||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 12.2 | - | - | - | |||||||||||||||
balance-sheet.row.other-current-liab | 995.11 | 0 | 1055.8 | 12.7 | |||||||||||||||
balance-sheet.row.total-non-current-liabilities | 5644.69 | 0 | 1774.7 | 1781 | |||||||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | |||||||||||||||
balance-sheet.row.capital-lease-obligations | 5597.1 | 0 | 1756.7 | 1729 | |||||||||||||||
balance-sheet.row.total-liab | 25036.2 | 0 | 8651.5 | 7664.8 | |||||||||||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | |||||||||||||||
balance-sheet.row.common-stock | 1788.07 | 0 | 596 | 596.2 | |||||||||||||||
balance-sheet.row.retained-earnings | 13959.3 | 0 | 4335.4 | 3504.2 | |||||||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 13324.74 | 7869.7 | 424.9 | 405.6 | |||||||||||||||
balance-sheet.row.other-total-stockholders-equity | 2145.4 | 124.5 | 2069.8 | 2071.7 | |||||||||||||||
balance-sheet.row.total-stockholders-equity | 31217.51 | 7994.2 | 7426.1 | 6577.7 | |||||||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 56598.67 | 7994.2 | 16179.1 | 14337.3 | |||||||||||||||
balance-sheet.row.minority-interest | 344.95 | 0 | 101.4 | 94.8 | |||||||||||||||
balance-sheet.row.total-equity | 31562.47 | 7994.2 | 7527.6 | 6672.5 | |||||||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 56598.67 | - | - | - | |||||||||||||||
Total Investments | 7065.78 | 6669 | 139.8 | 107.2 | |||||||||||||||
balance-sheet.row.total-debt | 9339.73 | 0 | 3094 | 2908 | |||||||||||||||
balance-sheet.row.net-debt | 2661.3 | 3334.5 | -417.6 | 672.9 |
Отчет за паричните потоци
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | 549.38 | 549.4 | 1013 | 917.2 | |||||||||||||||
cash-flows.row.depreciation-and-amortization | 78.29 | 0 | 1000.6 | 1087.8 | |||||||||||||||
cash-flows.row.deferred-income-tax | -78.96 | 0 | -35.1 | -27.3 | |||||||||||||||
cash-flows.row.stock-based-compensation | 3.79 | 0 | 14.2 | 40.4 | |||||||||||||||
cash-flows.row.change-in-working-capital | 0 | 0 | -9.7 | -603.9 | |||||||||||||||
cash-flows.row.account-receivables | 0 | 0 | -765.8 | -739.7 | |||||||||||||||
cash-flows.row.inventory | 0 | 0 | -234.9 | -1236.8 | |||||||||||||||
cash-flows.row.account-payables | 0 | 0 | 1026.1 | 1399.9 | |||||||||||||||
cash-flows.row.other-working-capital | 0 | 0 | -35.1 | -27.3 | |||||||||||||||
cash-flows.row.other-non-cash-items | 663.5 | -549.4 | 514.1 | 377.5 | |||||||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | 1212.21 | 0 | 0 | 0 | |||||||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | -168.13 | 0 | -349 | -391.6 | |||||||||||||||
cash-flows.row.acquisitions-net | 31.97 | 0 | -4.7 | -65.1 | |||||||||||||||
cash-flows.row.purchases-of-investments | -10.25 | 0 | -980.5 | -1976.5 | |||||||||||||||
cash-flows.row.sales-maturities-of-investments | -31.97 | 0 | 1207.2 | 2901.8 | |||||||||||||||
cash-flows.row.other-investing-activites | -120.67 | 0 | -94.7 | -336.9 | |||||||||||||||
cash-flows.row.net-cash-used-for-investing-activites | -299.04 | 0 | -221.7 | 131.7 | |||||||||||||||
cash-flows.row.debt-repayment | -337.3 | 0 | -207.9 | -137.1 | |||||||||||||||
cash-flows.row.common-stock-issued | 0 | 0 | 2 | 0.1 | |||||||||||||||
cash-flows.row.common-stock-repurchased | 0 | 0 | -2 | -0.1 | |||||||||||||||
cash-flows.row.dividends-paid | -260.13 | 0 | -191.6 | -180.9 | |||||||||||||||
cash-flows.row.other-financing-activites | -491.05 | 0 | -678.6 | -986.8 | |||||||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | -1088.47 | 0 | -1078.2 | -1304.8 | |||||||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 0.42 | 0 | 0.3 | -0.1 | |||||||||||||||
cash-flows.row.net-change-in-cash | -46.39 | 0 | 1197.5 | 618.5 | |||||||||||||||
cash-flows.row.cash-at-end-of-period | 11134.11 | 2859.5 | 2859.5 | 1661.9 | |||||||||||||||
cash-flows.row.cash-at-beginning-of-period | 11180.5 | 2859.5 | 1661.9 | 1043.5 | |||||||||||||||
cash-flows.row.operating-cash-flow | 1212.21 | 0 | 2497.1 | 1791.7 | |||||||||||||||
cash-flows.row.capital-expenditure | -168.13 | 0 | -349 | -391.6 | |||||||||||||||
cash-flows.row.free-cash-flow | 1044.09 | 0 | 2148.1 | 1400 |
Ред за отчет за приходите
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 17380.31 | 17380.3 | 17431.6 | 14587.4 | |||||||||||||||
income-statement-row.row.cost-of-revenue | 17136.66 | 0 | 11322.3 | 9196.5 | |||||||||||||||
income-statement-row.row.gross-profit | 243.65 | 17380.3 | 6109.3 | 5390.9 | |||||||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | |||||||||||||||
income-statement-row.row.research-development | 15.3 | - | - | - | |||||||||||||||
income-statement-row.row.selling-general-administrative | 641.68 | - | - | - | |||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 5991.66 | - | - | - | |||||||||||||||
income-statement-row.row.other-expenses | -4580.64 | -16595 | 349.1 | 320.6 | |||||||||||||||
income-statement-row.row.operating-expenses | 7877.55 | 16595 | 4496.8 | 4091.3 | |||||||||||||||
income-statement-row.row.cost-and-expenses | 16445.88 | 16595 | 15819.1 | 13287.8 | |||||||||||||||
income-statement-row.row.interest-income | -58.93 | 0 | 53.4 | 39.2 | |||||||||||||||
income-statement-row.row.interest-expense | 94.62 | 0 | 147.1 | 136.2 | |||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 5991.66 | - | - | - | |||||||||||||||
income-statement-row.row.total-other-income-expensenet | -83.64 | -83.6 | -426.9 | 28.6 | |||||||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | |||||||||||||||
income-statement-row.row.other-operating-expenses | -4580.64 | -16595 | 349.1 | 320.6 | |||||||||||||||
income-statement-row.row.total-operating-expenses | -83.64 | -83.6 | -426.9 | 28.6 | |||||||||||||||
income-statement-row.row.interest-expense | 94.62 | 0 | 147.1 | 136.2 | |||||||||||||||
income-statement-row.row.depreciation-and-amortization | 219.25 | 103 | 1000.6 | 1397.7 | |||||||||||||||
income-statement-row.row.ebitda-caps | 862.24 | - | - | - | |||||||||||||||
income-statement-row.row.operating-income | 785.27 | 785.3 | 1661.9 | 1067.9 | |||||||||||||||
income-statement-row.row.income-before-tax | 701.63 | 701.6 | 1235 | 1096.5 | |||||||||||||||
income-statement-row.row.income-tax-expense | 152.25 | 152.3 | 222 | 179.3 | |||||||||||||||
income-statement-row.row.net-income | 543.49 | 549.4 | 1010 | 921.6 |
Често задавани въпроси
Какво е Yixintang Pharmaceutical Group Co., Ltd. (002727.SZ) общи активи?
Yixintang Pharmaceutical Group Co., Ltd. (002727.SZ) общите активи са 0.000.
Какъв е годишният приход на предприятието?
Годишните приходи са 8704775099.000.
Какъв е маржът на печалбата на предприятието?
Маржът на печалбата на фирмата е 1.726.
Какъв е свободният паричен поток на компанията?
Свободният паричен поток е 1.726.
Какъв е маржът на нетната печалба на предприятието?
Маржът на нетната печалба е 0.031.
Какъв е общият приход на предприятието?
Общият приход е 0.045.
Каква е Yixintang Pharmaceutical Group Co., Ltd. (002727.SZ) нетна печалба (нетен доход)?
Нетната печалба (нетният доход) е 549377465.000.
Какъв е общият дълг на фирмата?
Общият дълг е 0.000.
Какъв е броят на оперативните разходи?
Оперативните разходи са 16595043480.000.
Какъв е броят на паричните средства на фирмата?
Паричните средства на предприятието са -3334516420.000.